Drug Profile
Research programme: viral haemorrhagic fever therapeutics - Integrated BioTherapeutics
Alternative Names: CA 45; FILOV; Filovirus equine immunoglobulin; FVM 04Latest Information Update: 10 May 2023
Price :
$50
*
At a glance
- Originator Integrated BioTherapeutics
- Developer Emergent BioSolutions; Integrated BioTherapeutics
- Class Antivirals; Immunoglobulins; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Viral haemorrhagic fevers
Most Recent Events
- 10 May 2023 No development reported - Preclinical for Viral haemorrhagic fevers in USA (Parenteral) prior to May 2023 (Integrated BioTherapeutics pipeline, May 2023)
- 10 Sep 2019 Preclinical trials in Viral haemorrhagic fevers in USA before September 2019 (Emergent Biosolutions pipeline, September 2019)
- 02 Mar 2017 Preclinical development for Ebola virus infections is ongoing USA